Changcheng Zhu

https://assets.montefioreeinstein.org/profiles/images/Zhu_Changcheng_MD_2x.jpg

First Name

Changcheng

Last Name

Zhu

NPI

1407936909

Faculty ID

10578

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Thoracic pathology, Head &amp; Neck Pathology, Gynecological Pathology and Lung Transplant Pathology<br /><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Lung cancer<br />

Elsevier Profile

EMR ID

4827

Is Open Scheduling

Off

Michael Yee

https://assets.montefioreeinstein.org/profiles/images/13771-michael-yee.jpg

First Name

Michael

Last Name

Yee

NPI

1699971085

Faculty ID

13771

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5456

Is Open Scheduling

Off

Kathleen D. Whitney

https://assets.montefioreeinstein.org/profiles/images/physphoto/Whitney_Kathleen_D_MD_3514.jpg

First Name

Kathleen

Last Name

Whitney

NPI

1821178328

Faculty ID

6789

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3851

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Jacqueline Weingarten-Arams

https://assets.montefioreeinstein.org/profiles/images/physphoto/Weingarten_Jacqueline_MD_420x504.jpg

First Name

Jacqueline

Last Name

Weingarten-Arams

NPI

1558447409

Faculty ID

4831

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Lab Website Link

EMR ID

3961

Biography

<p>Jacqueline Weingarten-Arams, MD, is an attending physician and Professor, Pediatrics at Montefiore Einstein. Dr. Weingarten-Arams&rsquo; pediatric critical care expertise focuses on cardiac critical care, acute hypoxemic respiratory failure, nutrition in critical illness and energy expenditure, cardiopulmonary resuscitation (quality CPR) and extracorporeal life support (ECMO).</p><p>After obtaining her Bachelor of Science in nutritional biochemistry at Cornell University in 1982, Dr. Weingarten-Arams earned her Doctor of Medicine at the same institution in 1986. She then completed her pediatric residency at Columbia University in 1990, where she was Chief Resident in her final year. Following this, Dr. Weingarten-Arams completed a fellowship in pediatric critical care medicine at New York Hospital Cornell University Medical College in 1996.</p><p>Dr. Weingarten-Arams research focus includes the use of deliberate simulated practice in improving outcomes in pediatric critical illness, pediatric resuscitation and pediatric airway management. Her other projects involve chronic critical illness, bioethics in pediatric critical care and oxidative injury in respiratory failure. She has been principal investigator and co-investigator on several research projects, and her work has been shared through numerous peer-reviewed publications and invited presentations.</p><p>Dr. Weingarten-Arams is a Diplomate of the National Board of Medical Examiners and the American Board of Pediatrics. She is a Fellow of the American Academy of Pediatrics and the American College of Chest Physicians. She is also a member of several professional organizations, including the American Medical Association, the Pediatric Cardiac Intensive Care Society and the Society of Critical Care Medicine. Dr. Weingarten-Arams has been named in Castle Connolly&rsquo;s &ldquo;Top Doctors: New York Metro Area&rdquo; for multiple years. In 2006, she was inducted into the Leo M. Davidoff Society and in 2019, Dr. Weingarten-Arams won the William Obrinsky Award for Excellence in Medical Student Education.</p>

Is Open Scheduling

Off

Yanhua Wang

https://assets.montefioreeinstein.org/profiles/images/Wang_Yanhua_MD_2x.jpg

First Name

Yanhua

Last Name

Wang

NPI

1689817397

Faculty ID

3701

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Areas of Research</strong>: Primary research areas are focused on identifying distinctive immunologic and molecular genetic diagnostic and prognostic markers of hematologic neoplasms.</p>
<p><strong>Professional Interests:</strong> Pathological diagnosis of hematopoietic abnormalities, including mature and immature lymphoma/leukemia; myeloproliferative/dysplastic myeloid neoplasms, plasma cell proliferative disorder and other hematological related abnormalities using flow cytometry, immunohistochemistry, cytogentic/FISH and molecular diagnostic tools.</p>
<p>&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Selected Recent Publications:</strong></p>
<p><strong>&nbsp;1.</strong><strong>&nbsp; &nbsp;&nbsp;</strong><strong>Yanghua Wang¹</strong>, Adam Gersten¹, Susana Moleirinho^2,3, Frank J. Gunn-Moore², Paul A. Reynolds³, Michael B. Prystowsky¹&nbsp;Fibroblasts in Head Neck Squamous Cell Carcinoma Associated with Peri-neural Invasion Have High Level Nuclear Yap Expression&nbsp; Academic Pathology, 2015<strong>2.&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<p><strong>2.</strong>&nbsp; &nbsp; Jose G.M. Arango, Shlomit Goldberg-Stein, <strong>Yanhua Wang</strong> Extranodal Rosai-Dorfman disease: Clinico-pathologic series of thirteen cases and review of the literature American Journal of Clinical Pathology, 2016; 0:1-11</p>
<p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Monica Zell,*, Amer Assal,*, Olga Derman, Noah Kornblum, Ramakrishna Battini, <strong>Yanhua Wang</strong>, Deepa M. Narasimhulu, Ioannis Mantzaris, Aditi Shastri, Amit Verma, Hilda Ye, IraBraunschweig, Murali Janakiram &nbsp;&nbsp;Adult T-Cell leukemia/lymphoma in the Caribbean cohort is adistinct clinical entity with dismal response to conventional chemotherapy Oncotarget, June 2016<strong> <strong>DOI: 10.18632/oncotarget.10223</strong></strong></p>
<p><strong>4.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J,&nbsp;<strong>Wang Y</strong>, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort. Leukemia. 2016 Apr 29. doi: 10.1038/leu.2016.74. [Epub ahead of print]</p>
<p><strong>5.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Monica Zell, Amer Assal, Olga Derman, Noah Kornblum, Ramakrishna Battini,<strong> Yanhua Wang</strong>, Deepa M. Narasimhulu, Ioannis Mantzaris, Aditi Shastri, Amit Verma, Hilda Ye, Ira Braunschweig, Murali Janakiram&nbsp;&nbsp; Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy.&nbsp; Oncotarget, Advance Publications 2016</p>
<p><strong>6.&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;<strong>Yanhua Wang</strong>, Samer Khader, Yonatan Mehlman, Yungtai Lo, Joseph Albanese, Howard Ratech Loss of &alpha;II and &beta;III Spectrin Isoforms in Body Fluids is Associated with Metastasis. Advances in Cytology &amp; Pathology, Volume 2 Issue 1 &ndash; 2017</p>
<p><strong>7.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Etan Marks, Yang Shi, <strong>Yanhua Wang</strong> CD117 (KIT) Is A Useful Marker in The Diagnosis of Plasmablastic Plasma Cell Myeloma, Histopathology, 2017, <strong>DOI:</strong><strong>&nbsp;</strong>10.1111/his.13196</p>
<p><strong>8.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Murali Janakiram , Amit Verma, <strong>Yanhua Wang</strong>, Anjali Budhathoki, Jaime Suarez Londono, Irina Murakhovskaya, Ira Braunschweig &amp; Caterina P.Minniti&nbsp; Accelerated leukemic transformation after haploidentical transplantation for hydroxyurea-treated sickle cell disease, Leukemia &amp; Lymphoma, DOI: 10.1080/10428194.2017.1324158</p>
<p><strong>9.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Zhonghua Li, M.D., Ph.D., John G. Pizzolo, B.S., <strong>Yanhua Wang</strong>, M.D., Ph.D.Utility of Cytocentrifugation Slides in the Flow Cytometry Laboratory: a Single Institution experience, Clinical Pathology Diangosis,&nbsp; Journal of Hematopathology, online, 2017</p>
<p><strong>10.&nbsp; </strong>Michael J. Licata, MD¹, Murali Janakiram, MD², Yanan Fang, MD¹, Urvi A. Shah, MD², Amit Verma, MD² and <strong>Yanhua Wang</strong>, MD Diagnostic Challenges of Western Adult T-Cell Leukemia/Lymphoma with Unusual Clinical Presentation - Clinical, Histological and Immunophenotypic Analysis, Leukemia &amp; Lymphoma, 2018 VOL. 59, NO. 5, 1188&ndash;1194 https://doi.org/10.1080/10428194.2017.1365862</p&gt;
<p><strong>11.&nbsp; </strong>Evan Himchak, Etan Marks, Yang Shi, <strong>Yanhua Wang</strong>, Did I miss one? Discovering Hidden Co-existing Hematological with Non-Hematological Malignancies, A Single Institutional Review of 100 Collision Tumors, <a title="International journal of surgical pathology." href="https://www.ncbi.nlm.nih.gov/pubmed/29320898">Int J Surg Pathol.</a>&nbsp;2018 Jan 1:1066896917752862. doi: 10.1177/1066896917752862. [Epub ahead of print]</p>
<p><strong>12.&nbsp; </strong>Jesus Anampa, Tamanna Haque, Irina Murakhovskaya, <strong>Yanhua Wang</strong>, Kimo Bachiashvili, Cristian Papazoglu, Kith Pradhan, Ulrich G. Steidl, Joseph A. Sparano, Amit Verma^{&nbsp;&nbsp;&nbsp;}Macrocytosis And Dysplastic Anemia Is Associated With The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib In Metastatic Breast Cancer, Haematologica , Published Ahead of Print on November 30, 2017, as doi:10.3324/haematol.2017.181941</p>
<p><strong>13.&nbsp; </strong>Shaomin Hu, James Szymanski, Zeina Khairy, Yungtai Lo, <strong>Yanhua Wang</strong> Breast pathology and mammography BI-RADS category correlation study &ndash; A single institute experience Annals of Diagnostic Pathology 35 (2018) 11-15</p>
<p><strong>14.&nbsp; </strong>Shah UA,&nbsp;Chung EY,&nbsp;Giricz O,&nbsp;Pradhan K,&nbsp;Kataoka K,&nbsp;Gordon-Mitchell S,&nbsp;Bhagat TD,&nbsp;Mai Y,&nbsp;Wei Y,&nbsp;Ishida E,&nbsp;Choudhary GS,&nbsp;Joseph A,&nbsp;Rice R,&nbsp;Gitego N,&nbsp;Parrish C,&nbsp;Bartenstein M,&nbsp;Goel S,&nbsp;Mantzaris I,&nbsp;Shastri A,&nbsp;Derman O,&nbsp;Binder A,&nbsp;Gritsman K,&nbsp;Kornblum N,&nbsp;Braunschweig I,&nbsp;Bhagat C,&nbsp;Hall J,&nbsp;Graber A,&nbsp;Ratner L,&nbsp;<strong>Wang Y,&nbsp;</strong>Ogawa S,&nbsp;Verma A,&nbsp;Ye BH,&nbsp;Janakiram M. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood.&nbsp;2018 Oct 4;132(14):1507-1518. doi: 10.1182/blood-2018-01-824607. Epub 2018 Aug 13.</p>
<h1>&nbsp;</h1>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>

EMR ID

5085

Is Open Scheduling

Off

Esperanza Villanueva-Siles

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/83dd1f30-84f7-11ef-b387-d348df9d586b.jpg

First Name

Esperanza

Last Name

Villanueva-Siles

NPI

1518047018

Faculty ID

10058

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4730

Is Open Scheduling

Off

Victoria Vapnyar

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/dd685560-3db5-11ec-b813-25aca5adcea8.jpg

First Name

Victoria

Last Name

Vapnyar

NPI

1740556133

Faculty ID

17135

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

101619

Is Open Scheduling

Off

Berrin Ustun

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ustun_Berrin_MD_11119532.jpg

First Name

Berrin

Last Name

Ustun

NPI

1568789394

Faculty ID

13617

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5648

Is Open Scheduling

Off

Audrey M. Uong

https://assets.montefioreeinstein.org/profiles/images/physphoto/Uong_Audrey_MD_420x504.jpg

First Name

Audrey

Last Name

Uong

NPI

1518387323

Faculty ID

15425

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Dr. Uong's&nbsp;clinical focus has been in pediatrics.

Research Focus

The care of hospitalized pediatric patients with asthma has been a main focus of research for Dr. Uong. She is also interested in researching the improvement of transitions of care in hospitalized pediatric patients.

Elsevier Profile

EMR ID

53070

Biography

<p>Audrey M. Uong, MD, is an Attending Physician, Division of Hospital Medicine at Children&rsquo;s Hospital at Montefiore (CHAM) and an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2019, her clinical focus has been in pediatrics.</p><p>In 2008, Dr. Uong received her Bachelor of Arts in Asian Languages and Civilizations from Amherst College. Her studies continued at New York Medical College, where she received her Doctor of Medicine in 2014. Following this, Dr. Uong continued her studies at Albert Einstein Medical College and received her Master of Science in Clinical Research Methods in 2019. She began her postgraduate training in 2014 with a 3-year internship and residency at Cohen Children&rsquo;s Medical Center. She then completed a fellowship in Pediatric Hospital Medicine at CHAM in 2019.</p><p>The care of hospitalized pediatric patients with asthma has been a main focus of research for Dr. Uong. She is also interested in researching the improvement of transitions of care in hospitalized pediatric patients. Her work has been published in numerous peer-reviewed journals and review articles, and has been presented nationally.</p><p>In 2019, Dr. Uong received the CHAM Research Day Oral Presentation Award, given to her from faculty judges for receiving top scores. Dr. Uong is board certified by the American Board of Pediatrics and is a member of numerous professional societies, including the American Academy of Pediatrics and the Academic Pediatric Association.</p>

Is Open Scheduling

Off